<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3610">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04378920</url>
  </required_header>
  <id_info>
    <org_study_id>2020-003</org_study_id>
    <secondary_id>2020-001393-30</secondary_id>
    <secondary_id>2020-A00900-39</secondary_id>
    <nct_id>NCT04378920</nct_id>
  </id_info>
  <brief_title>A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes</brief_title>
  <official_title>A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de cancérologie Strasbourg Europe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LEAF4Life LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de cancérologie Strasbourg Europe</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label phase II study of treatment with LEAF-4L6715 in patients who experience&#xD;
      severe acute respiratory distress syndrome (ARDS) due to COVID-19, Sepsis or other Causes.&#xD;
      The purpose of this study is to evaluate the improvement in PaO2/FiO2 by more than 25% in&#xD;
      patients treated with LEAF-4L6715.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient is treated with LEAF-4L6715, a liposomal transcrocetin. The liposomal formulation&#xD;
      allows for a gradual release of the free drug, thereby facilitating less frequent dosing.&#xD;
&#xD;
      Pharmacokinetic assessment will be carried out to identify an optimal dose and schedule.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients showing an increase of at least 25% of PaO2/FiO2 ratio</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>proportion of patients with a PaO2/FiO2 ratio above 200 mm Hg</measure>
    <time_frame>24, 48 and 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all cause mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>COVID19, Sepsis or Other Causes</condition>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>4L6715</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>exploring various doses of LEAF-4L6715</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEAF-4L6715</intervention_name>
    <description>LEAF-4L6715</description>
    <arm_group_label>4L6715</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent from the patient or patient's legal representative must be&#xD;
             obtained prior to any procedures, as the likelihood of patients being able to provide&#xD;
             consent is very limited&#xD;
&#xD;
          2. Patients must be ≥ 18 years old&#xD;
&#xD;
          3. Patient must have acute respiratory distress syndrome as defined, with a PaO2/FiO2&#xD;
             ratio of less than 200 mm Hg&#xD;
&#xD;
          4. Patient must be under artificial ventilation support (including patient under&#xD;
             OptiflowTM Nasal High Flow device or an equivalent device)&#xD;
&#xD;
          5. Patient must have a life expectancy of at least 24 hours&#xD;
&#xD;
          6. Patients should have normal liver function as defined by ALT, AST and alkaline&#xD;
             phosphate less than 3 ULN for the institution&#xD;
&#xD;
          7. Patient must have platelet count above &gt;100,000 cells/mm3, hemoglobin &gt; 8 g/dL and an&#xD;
             absolute neutrophil count (ANC) of &gt; 1000 cells/mm3&#xD;
&#xD;
          8. Patients requiring dialysis due to renal impairment in cohort 3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient is enrolled in any other therapeutic clinical trial with the same endpoints.&#xD;
             All observational studies or study with limited invasive methods (Pharmacokinetic&#xD;
             studies, monitoring of virus charges studies, biological monitoring studies ….) are&#xD;
             allowed&#xD;
&#xD;
          2. Patient is pregnant or breast-feeding&#xD;
&#xD;
          3. Patient has a known hypersensitivity to crocetins, LEAF-4L6715 or any of its&#xD;
             excipients&#xD;
&#xD;
          4. Patients with hemoglobinopathy&#xD;
&#xD;
          5. Patients receiving extracorporeal membrane oxygenation (ECMO)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Valerie SARTORI</last_name>
    <phone>368767223</phone>
    <phone_ext>33</phone_ext>
    <email>v.sartori@icans.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manon VOEGELIN, PhD</last_name>
    <phone>368767360</phone>
    <phone_ext>33</phone_ext>
    <email>promotion-rc@icans.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie SARTORI</last_name>
      <phone>368767223</phone>
      <phone_ext>33</phone_ext>
      <email>v.sartori@icans.eu</email>
    </contact>
    <contact_backup>
      <last_name>Manon VOEGELIN</last_name>
      <phone>368767360</phone>
      <phone_ext>33</phone_ext>
      <email>m.voegelin@icans.eu</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Michel MERTES, PhD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier COLLANGE, PhD MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie Strasbourg Europe</name>
      <address>
        <city>Strasbourg</city>
        <zip>67033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerie SARTORI</last_name>
      <phone>368767223</phone>
      <phone_ext>33</phone_ext>
      <email>v.sartori@icans.eu</email>
    </contact>
    <contact_backup>
      <last_name>Manon VOEGELIN</last_name>
      <phone>368767360</phone>
      <phone_ext>33</phone_ext>
      <email>m.voegelin@icans.eu</email>
    </contact_backup>
    <investigator>
      <last_name>Vitaliy CHABAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 5, 2020</study_first_submitted>
  <study_first_submitted_qc>May 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2020</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

